Good MorningEquity markets rebounded on Monday as investors hoped for FOMC leniency. The budding banking crisis is the first sign of economic cracking and, for some, a reason the FOMC should quit hiking rates. The caveat is that inflation is still high, and the latest data supports the Fed's current policy stance. However, the FOMC may only raise by 25 basis points but issue a firm statement that says the committee will act when the data is hot.
A new round of aid for trouble bank First Republic helped soothe fears of contagion. A consortium of banks led by JPMorgan Chase & Co. is seeking ways to raise capital for the bank and shore up its balance sheet. Among the possibilities are dilutive share sales and an outright bank sale. Meanwhile, the banking fallout has investors in the EU on edge, which is another sign that global economic conditions are on the brink of collapse. Featured: Little-Known Microcap Enters the Prediction Markets Boom (Ad) 
|
Healthcare | | Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com’s dividend screener will turn up names like Comcast (NASDAQ: CMCSA), Bristol-Myers Squibb (NYSE: BMY), and Amgen (NYSE: AMGN), among others. These compani... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
|
Markets | |
It’s no secret to many investors that some of the largest gains come from investing in small-cap stocks. These stocks can get overlooked because of their market capitalization. But that would be a mistake. Historical patterns show that frequently small-cap stocks are the ones that perform th... Read the Full Story |
|
Consumer Discretionary | |
Build-A-Bear Workshop Inc. (NYSE: BBW) started as a niche retailer in shopping malls selling plush dolls that children could bring to life in the store by adding stuffing, a heart with a recordable message, along with other customizable options. The customer can name the doll, buy clothing and acc... Read the Full Story |
|
From Our Partners | | On January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adversaries. China controls more than 90% of global rare earth processing capacity, while the U.S. imports 100% of its titanium sponge.
SAGA Metals has drilled more than 23,000 meters at its Radar project, with all 92 drill holes intersecting mineralization. A maiden mineral resource estimate is expected in Q4 2026, alongside ongoing drilling at the Wolverine heavy rare earth project. | | See what's next for SAGA Metals before the deadline hits |
|
Finance | |
First, it was Silicon Valley Bank. Then Signature Bank. First Republic Bank is assumed to be the next domino to fall in the evolving U.S. banking crisis.
Whether higher interest rates or company mismanagement are to blame, one thing is clear — people are concerned. Worried about the securi... Read the Full Story |
|
Technology | |
The entire chip sector shows a bottom and is on the cusp of reversal, with NVIDIA (NASDAQ: NVDA) in the lead. The company’s Q4 results were better than expected due to unexpected strengths that led to solid guidance. The stock is up about 150% from its latest bottom and on track to hit high... Read the Full Story |
|
From Our Partners | | A new tool called Oracle tracks insider bets hidden in the predictions market, flagging which stocks and options could be affected.
During beta testing, Oracle identified notable short-term moves including USO up 39% in four days, PLTR up 43% in a day, and WEN up 67% in two days, all through a regular brokerage account.
See how Oracle spots these hidden insider bets before they make headlines. | | Get free access to Oracle and see the data now |
|
Markets | |
First Republic Bank (NYSE: FRC) may be a fine investment, but it has been nothing but headaches for investors lately, and the tough times are not over. The latest news is a new capital raise led by JPMorgan Chase & Co. (NYSE: JPM) CEO Jamie Dimon. Dimon is reportedly working on assembling a co... Read the Full Story |
|
Consumer Discretionary | |
Mullen Automotive is an early-phase EV start-up with no production, and no revenue, so is not much of an investment. Buying the company is speculation, at times compelling speculation, because production and revenue appear to be close at hand. The company has several irons in the fire, and it will... Read the Full Story |
|
Markets | |
Bitcoin is breaking out above its critical $25,000 level, which has been acting as stubborn upside resistance for the last nine months. Briefly trading above $27,000 on Friday morning, Bitcoin looks like it's trying to mount another bull trend.
Like gold, Bitcoin is a proxy for skepticism of frac... Read the Full Story |
|
Consumer Staples | |
General Mills (NYSE: GIS) advanced to a new all-time high following the FQ2 earnings release but has since retreated to retest support. The set-up has the market trading at the 150-day EMA and ready to fire another trend-following signal. The catalyst for this move could be the Q3 earnings due out... Read the Full Story |
|
Consumer Discretionary | |
Foot Locker (NYSE: FL) has been muscling through the pain of inflation, supply chain hiccups, and an uncertain economic environment to come out ahead. The company has been working to reposition itself for the times, and those efforts are clearly paying off. The Q4 results are tepid; headwinds are ... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
